AI Article Synopsis
- * There are ongoing efforts to better define treatment guidelines, especially for vulnerable groups like children, pregnant women, and the elderly, who often lack sufficient information in existing literature.
- * This review aims to update knowledge on chronic spontaneous urticaria (CSU) in these populations by discussing how common it is, important diagnosis factors, and potential treatment strategies.
Article Abstract
Chronic urticaria is an inflammatory skin disorder defined by the presence of evanescent erythematous pruritic wheals, angioedema, or both. While treatment guidelines are continuing to become more clearly defined, there is still a gap in the medical literature surrounding chronic spontaneous urticaria (CSU) treatment in vulnerable populations such as children (aged 0-18 years), pregnant women, and the elderly (aged >65 years). The purpose of this review is to provide an update on CSU in each of these special population categories by defining prevalence, identifying diagnostic considerations, and exploring current and future management options.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.iac.2024.03.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Disease control and quality of life in chronic spontaneous urticaria and recurrent angioedema are strongly linked, but not in all patients.
Clin Transl Allergy
January 2025
Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Background: Patient-reported outcome measures (PROMs) help to assess disease control and quality of life (QoL) in chronic spontaneous urticaria (CSU) and recurrent angioedema (RA). This study aimed to assess the correlation between two different concepts: disease control and QoL, using disease-specific PROMs.
Methods: We analyzed data from 445 CSU and 330 RA patients who completed both a disease control and QoL PROM as part of the clinical routine.
Think again about cyclosporine for chronic spontaneous urticaria.
Ann Allergy Asthma Immunol
January 2025
Pediatric Department, Division of Respiratory Medicine, University of California San Diego, Encinitas, California. Electronic address:
Comparison of the characteristics of patients with chronic urticaria receiving standard- or high-dose omalizumab.
Eur Ann Allergy Clin Immunol
January 2025
Division of Allergy and Clinical Immunology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
In patients whose chronic urticaria (CU) cannot be controlled with omalizumab 300 mg and antihistamines, the dose can be increased up to 600 mg. The study aimed to compare the clinical characteristics of patients receiving 300 mg versus higher doses of omalizumab, and to evaluate baseline predictors for updosing. A total of 159 patients who have been followed up at a tertiary care allergy center and received omalizumab for at least 12 months were included.
View Article and Find Full Text PDFProvocation test on stairs: a new accessible method to cholinergic urticaria diagnosis.
Eur Ann Allergy Clin Immunol
January 2025
Immunology Service, Hospital Universitário Clementino Fraga Filho (HUCFF-UFRJ), Rio de Janeiro, Brazil.
Cholinergic urticaria (CholU) is characterized by itching and/or stinging, painful micro wheals due to systemic heating. There are two standardized protocols to diagnose CholU using an exercise bike with heart rate or warming passive. The objective is to provide an affordable, new, low-tech test to assist the diagnostic.
View Article and Find Full Text PDFCost-of-illness analysis of chronic urticaria clinical management in five countries of Latin America.
Clin Transl Allergy
January 2025
Institute for Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Introduction: Chronic spontaneous urticaria (CSU) is a disease with a high impact on the quality of life of patients. There are some evaluations of the economic cost of the disease in developed countries, but there is little information about the economic cost of the disease in developing countries. Our aim was to assess the economic diagnostic and therapeutic expenses of CSU in five Latin American (LA) countries.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!